Navigation Links
New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
Date:8/27/2007

stage medicinal chemistry. The scarcity of intellectual and financial capital for this essential part of the drug discovery process between the lab bench and the clinical drug development process is Australia's great funding gap.

"CTx will provide an integrated and coherent pathway for drug discovery, commercialisation and clinical development. Currently, the standard model of drug development can present a frustrating conundrum for medical researchers. The discovery of a new compound, which may well possess the qualities to be transformed into a new drug, requires further substantial investment to properly demonstrate its potential. At this point, research organisations operating on tight budgets and with limited development experience and/or capabilities feel that further investment is beyond their grasp. In addition, pharmaceutical companies are reluctant to take on the development of compounds at a very early stage because their likelihood of success has not been established. Consequently, a promising compound often fails to reach even the early clinical testing phase."

Dr Ian Street, Chief Scientific Officer of CTx, adds, "That's where CTx comes in. We have a unique combination of skills, ranging from independent, expert scientific assessment and validation through to drug development, commercialisation and clinical application. CTx is now establishing its drug discovery operations in key locations throughout Australia and has already identified a number of exciting projects to initiate its development programs."

For more information

Cancer Therapeutics CRC Pty Ltd CEO

Dr Julian Clark Tel: +61-3-9345-2612

e-mail: jclark@wehi.edu.au

Notes to editors:

CTx has created a world-class translational research organisation headquartered at The Walter and Eliza Hall Institute's Biotechnology Centre at Bundoora, in north-eastern Melbourne, Victoria and brings together Australia's fo
'/>"/>

SOURCE Cancer Therapeutics CRC Pty Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
3. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
4. FDA Announces Results of Investigation Into Illegal Promotion of OxyContin by The Purdue Frederick Company, Inc.
5. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
6. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
7. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
8. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
9. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
10. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
11. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- Market Research ... Industry, 2009-2019 is a professional and in-depth market ... Scanner industry . The report firstly reviews the ... classification, application and manufacturing technology. The report then ... Crystallography Scanner listing their product specification, capacity, Production ...
(Date:8/29/2014)... 2014 The Competitive Intelligence (CI) function is ... CI leaders who adjust will succeed, and those who ... Best Practices, LLC study CI leaders from 32 biopharmaceutical ... - Use secondary research whenever possible - it,s ... - Internal staff who are creative thinkers provide the ...
(Date:8/29/2014)... , Aug. 29, 2014  A Boston Scientific ... study on stent removability and preliminary long term ... published in the August issue of the peer-reviewed ... 1 is being conducted in 11 countries ... covered self-expanding metal stents (FCSEMS) after extended indwell ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4
... EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany , ... for filing the New Drug Application (NDA) for Cladribine Tablets as a ... , , ... Review designation by the FDA, which means the review period for the ...
... , SHANGHAI , July ... WX ) today announced that RiskMetrics Group,s ISS Proxy Advisory ... has recommended that WuXi shareholders vote FOR Charles River,s proposed,acquisition ... Proxy,Governance, previously recommended that WuXi shareholders vote FOR the,transaction. , ...
Cached Medicine Technology:EMD Serono, Inc.: FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of MS 2EMD Serono, Inc.: FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of MS 3EMD Serono, Inc.: FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of MS 4EMD Serono, Inc.: FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of MS 5ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 2ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 3ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 4ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 5
(Date:9/1/2014)... Currently, scientists continue to face fundamental ... disease (AD), which reflects their poor understanding of ... of the disease, especially in its early stages, ... In 2014, after decades that have witnessed ... medicine world, there are still no disease-modifying therapies ...
(Date:9/1/2014)... Dennis Thompson HealthDay Reporter ... experimental Ebola drug previously given to two American aid workers ... virus in laboratory tests, researchers report. The drug, ZMapp, ... if they didn,t get the medication until five days after ... Ebola who were days or even hours away from death, ...
(Date:9/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... AND GLOBAL MARKETS , the global market for blood-brain ... is expected to reach $38.7 million in 2014. This ... 2019, which is equivalent to 64.9% compound annual growth ... (RMT) segment is forecasted to grow at a CAGR ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Top10BestSEOHosting.com ... evaluating many web host suppliers carefully, Top10BestSEOHosting.com is ... are the best web hosting suppliers in 2014. ... old clients with a top-of-the-line shared hosting plan. ... an easy-to-use platform that is affordable, accessible and ...
(Date:9/1/2014)... 01, 2014 Pastor Thompson is an ordained ... Eagle Village. He is a licensed minister through the Church ... past twenty years in New Mexico, Colorado and North Dakota. ... marriage this year. He also has two beautiful daughters, ... in Pastoral Ministry from Nazarene Bible College, in Colorado Springs ...
Breaking Medicine News(10 mins):Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2
... cosmetics shows it may have prevented, treated eye infections ... eye makeup worn thousands of years ago by Queen ... used to enhance beauty alone: New research suggests that ... eye disease. , Some ancient Egyptians thought their ...
... ... its’ addition of three exceptional leaders to their management team. Anne Reynolds and ... aboard as the Client Accounting Manager. , ... Columbus, OH (PRWEB) January 22, 2010 -- ADVOCATE, the premier ...
... ... identified brain networks damaged in Parkinson’s disease have new evidence that these systems become ... appear to respond in a last ditch attempt to rescue the brain. , ... Manhasset, NY (Vocus) January ...
... Jan. 22 Healthcare Trust of America, Inc. ... execution of a purchase and sale agreement to acquire an ... Georgia for approximately $19,550,000 . The closing of ... The medical office portfolio is 94% leased and is on ...
... Pa. , Jan. 22 ReSearch Pharmaceutical Services, Inc. ... and Steven Bell , Chief Financial Officer, will present at ... 25–27, 2010 in New York City .   , The ... 11:45 am, EST .  Mr. Perlman will also participate in ...
... find , FRIDAY, Jan. 22 (HealthDay News) -- Environment ... children,s reading skills, a new study finds. , "We ... learning, but children who come into school with poor ... author Stephen Petrill, a professor of human development and ...
Cached Medicine News:Health News:Explosive Growth Fuels Expansion of ADVOCATE's Management Team 2Health News:Explosive Growth Fuels Expansion of ADVOCATE's Management Team 3Health News:Brain Abnormalities in Parkinson's Patients Develop Before Symptoms Occur, According to Feinstein Scientists 2Health News:Brain Abnormalities in Parkinson's Patients Develop Before Symptoms Occur, According to Feinstein Scientists 3Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia 3Health News:ReSearch Pharmaceutical Services, Inc. to Present at Jefferies 2010 Global Healthcare Conference 2Health News:Environment Crucial to Boosting Child's Reading Skills 2
Porous foundation 480 series....
Cemented foundation 460 series....
Porous foundation 440 series....
The AcuMatch M-Series modular femoral stem is a unique, innovative three-piece modular stem designed to address even the most complicated of clinical indications....
Medicine Products: